SRR656564
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.512
- MYOGENESIS+0.488
- ANGIOGENESIS+0.455
- KRAS_SIGNALING_DN+0.452
- COAGULATION+0.426
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.379
- APICAL_SURFACE+0.376
- TNFA_SIGNALING_VIA_NFKB+0.349
- HEDGEHOG_SIGNALING+0.346
- INFLAMMATORY_RESPONSE+0.315
Top 10 suppressed
- PROTEIN_SECRETION-0.475
- DNA_REPAIR-0.464
- G2M_CHECKPOINT-0.455
- MYC_TARGETS_V1-0.452
- UNFOLDED_PROTEIN_RESPONSE-0.420
- E2F_TARGETS-0.418
- WNT_BETA_CATENIN_SIGNALING-0.413
- MITOTIC_SPINDLE-0.411
- MYC_TARGETS_V2-0.357
- INTERFERON_ALPHA_RESPONSE-0.333
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR659780 | GTEX | — | 0.945 |
| 2 | SRR662725 | GTEX | — | 0.935 |
| 3 | SRR662007 | GTEX | — | 0.932 |
| 4 | SRR660330 | GTEX | — | 0.916 |
| 5 | SRR1319019 | GTEX | — | 0.916 |
| 6 | SRR1476571 | GTEX | — | 0.911 |
| 7 | SRR1359171 | GTEX | — | 0.909 |
| 8 | SRR1418818 | GTEX | — | 0.905 |
| 9 | SRR1085662 | GTEX | — | 0.901 |
| 10 | SRR1335707 | GTEX | — | 0.897 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.512 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.488 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.455 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.452 | Remibrutinib | — uncovered |
| COAGULATION | 0.426 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.379 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.376 | Temsirolimus | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.349 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.346 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.315 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.311 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.287 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.235 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.234 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.234 | Inavolisib | — uncovered |
| COMPLEMENT | 0.233 | Inavolisib | — uncovered |
| HYPOXIA | 0.212 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.202 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.146 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.135 | Idelalisib | — uncovered |